Genetics and metabolic cardiomyopathies

Herz

Volumn 37, Issue 6, 2012, Pages 598-611

  Wicks, E C ^a   Elliott, P M ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiomyopathy; Genetics; Inborn errors; Metabolism

Indexed keywords

AMINO ACID; CARBOXYLIC ACID; CARNITINE; CHOLESTEROL; FATTY ACID; GLYCOGEN; GLYCOPROTEIN;

CARDIOMYOPATHY; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; CONGENITAL DISORDER OF GLYCOSYLATION; DANON DISEASE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ELECTRON TRANSPORT; FABRY DISEASE; FATTY ACID OXIDATION; GAUCHER DISEASE; GENE MUTATION; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; HEART ARRHYTHMIA; HEART MUSCLE METABOLISM; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INBORN ERROR OF METABOLISM; MAROTEAUX LAMY SYNDROME; MITOCHONDRIAL CARDIOMYOPATHY; MORQUIO SYNDROME; MUCOLIPIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE 7; MYOCARDIAL DISEASE; PEROXISOME STORAGE DISEASE; PRKAG 2 DISEASE; RESPIRATORY CHAIN; REVIEW; SANFILIPPO SYNDROME; STORAGE DISEASE; VALVULAR HEART DISEASE;

CARDIOMYOPATHIES; COMPUTER SIMULATION; GENETIC PREDISPOSITION TO DISEASE; HEART; HUMANS; METABOLISM, INBORN ERRORS; MODELS, CARDIOVASCULAR; MODELS, GENETIC;

EID: 84867753094     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3659-0     Document Type: Review

References (68)

1. Cox GF (2007) Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 24(1):15-25
2. Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85(3):1093-1129
3. Bonow R MD, Zipes D, Libby P (2011) Braunwald's heart disease: a textbook of cardiovascular medicine. Vol. 2, 9. edn. Elsevier
4. Barth PG, et al. (2004) X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet 126A(4):349-354 (Part A)
5. Breunig F, Wanner C (2008) Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J Nephrol 21(1):32-37
6. Nishino I, et al. (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406(6798):906-910
7. Ibdah JA, Yang Z, Bennett MJ (2000) Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 71(1-2):182-189
8. Saudubray JM, et al. (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 22(4):488-502
9. Olsen RK, et al. (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130(Pt 8):2045-2054
10. Roe CR, et al. (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110(2):259-269
11. Bonnefont JP, et al. (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25(5-6):495-520
12. Tein I (2003) Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 26(2-3):147-169
13. Huss JM, Kelly DP (2005) Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115(3):547-555
14. Koopman WJ, Willems PH, Smeitink JA (2012) Monogenic mitochondrial disorders. N Engl J Med 366(12):1132-1141
15. Anan R, et al. (1995) Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation 91(4):955-961
16. Holmgren D, et al. (2003) Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 24(3):280-288
17. Scaglia F, et al. (2004) Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 114(4):925-931
18. Yeager AM (2002) Allogeneic hematopoietic cell transplantation for inborn metabolic diseases. Ann Hematol 81(Suppl 2):16-19
19. Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67(18):2697-2716
20. Winchester B, Vellodi A, Young E (2000) The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 28(2):150-154
21. Butters TD, et al. (2003) Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos Trans R Soc B-Biol Sci 358(1433):927-945
22. Fan JQ (2007) Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins. FEBS J 274(19):4943
23. Grabowski GA (2008) Treatment perspectives for the lysosomal storage diseases. Expert Opin Emerg Drugs 13(1):197-211
24. Mohan UR, et al. (2002) Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 91(7):799-804
25. Stephan MJ, et al. (1989) Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. Am J Dis Child 143(7):782-784
26. Hirth A, Berg A, Greve G (2007) Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 30(5):820
27. Soliman OI, et al. (2007) Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I. J Inherit Metab Dis 30(5):750-757
28. Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6(3):489-506
29. Braunlin EA, Berry JM, Whitley CB (2006) Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98(3):416-418
30. Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120(2):405-418
31. Wraith JE, et al. (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167(3):267-277
32. Hishitani T, et al. (2000) Sudden death in Hunter syndrome caused by complete atrioventricular block. J Pediatr 136(2):268-269
33. Muenzer J, et al. (1993) Severe mitral insufficiency in mucopolysaccharidosis type III-B (Sanfilippo syndrome). Pediatr Cardiol 14(2):130-132
34. Valstar MJ, et al. (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis
35. George R, et al. (2001) Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation. Clin Genet 59(5):360-363
36. Kampmann C, et al. (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97(4):463-469
37. Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93(4):528-535
38. Hughes DA, et al. (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153-158
39. Grunewald S (2007) Congenital disorders of glycosylation: rapidly enlarging group of (neuro)metabolic disorders. Early Hum Dev 83(12):825-830
40. Lin AE, et al. (1997) Cardiovascular malformations in Smith-Lemli-Opitz syndrome. Am J Med Genet 68(3):270-278
41. Kollberg G, et al. (2007) Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 357(15):1507-1514
42. Regalado JJ, Rodriguez MM, Ferrer PL (1999) Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency. Pediatr Cardiol 20(4):304-307
43. Hermans MM, et al. (2004) Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23(1):47-56
44. Winchester B, et al. (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93(3):275-281
45. Ansong AK, et al. (2006) Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 8(5):297-301
46. Kishnani PS, et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68(2):99-109
47. Danon MJ, et al. (1981) Lysosomal glycogen storage disease with normal acid maltase. Neurology 31(1):51-57
48. Kooi AJ van der, et al. (2008) Extension of the clinical spectrum of Danon disease. Neurology 70(16):1358-1359
49. Shen JJ, Chen YT (2002) Molecular characterization of glycogen storage disease type III. Curr Mol Med 2(2):167-175
50. Carvalho JS, et al. (1993) Cardiomyopathy of glycogen storage disease type III. Heart Vessels 8(3):155-159
51. Moon JC, et al. (2003) Images in cardiovascular medicine. Myocardial fibrosis in glycogen storage disease type III. Circulation 107(7):e47
52. Moses SW, Parvari R (2002) The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2(2):177-188
53. Ewert R, et al. (1999) Glycogenosis type IV as a seldom cause of cardiomyopathy - report about a successful heart transplantation. Z Kardiol 88(10):850-856
54. Arad M, et al. (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109(3):357-362
55. Murphy RT, et al. (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45(6):922-930
56. Gilbert-Barness E (2004) Review: metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci 34(1):15-34
57. Simma B, Sperl W, Hammerer I (1990) GM1 gangliosidosis and dilated cardiomyopathy. Klin Padiatr 202(3):183-185
58. Morrone A, et al. (2000) beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat 15(4):354-366
59. Bhattacharya K, Gibson SC, Pathi VL (2005) Mitral valve replacement for mitral stenosis secondary to Hunter's syndrome. Ann Thorac Surg 80(5):1911-1912
60. Barshes NR, et al. (2006) Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review. Pediatr Transplant 10(7):773-781
61. Cederbaum SD, et al. (2002) Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab 77(3):195-201
62. Chalmers RA, et al. (1997) Mitochondrial carnitine-acylcarnitine translocase deficiency presenting as sudden neonatal death. J Pediatr 131(2):220-225
63. Pierre G, et al. (2007) Prospective treatment in carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis 30(5):815
64. Guertl B, Noehammer C, Hoefler G (2000) Metabolic cardiomyopathies. Int J Exp Pathol 81(6):349-372
65. Ratliff NB, et al. (2002) Cardiac arrest in a young marathon runner. Lancet 360(9332):542
66. Djouadi F, et al. (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54(4):446-451
67. Frerman FE, Goodman S (2001) Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxireductase:glutaric aciduria type II. In: Scriver, Beaudet, et al. (eds) The metabolic and molecular baisi of inherited disease. 8th edn. McGraw-Hill, pp 2357-2365
68. Van Hove JL, et al. (2003) D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 361(9367):1433-1435